Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers-Reference-Cited by-同舟云学术

Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers

Published:2021-08-07 Issue:13 Volume:28 Page:8567-8578
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Walker Brett S.,Sutton Thomas L.,Zarour Luai,Hunter John G.,Wood Stephanie G.,Tsikitis V. Liana,Herzig Daniel O.,Lopez Charles D.,Chen Emerson Y.,Mayo Skye C.,Wong Melissa H.

Funder

U.S. Department of Defense

Oregon Health and Science University

National Cancer Institute

Newton Esophageal Cancer Foundation

Collins Medical Trust

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-021-10379-2.pdf

Reference45 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654.

2. Gast CE, et al. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Adv. 2018;4:7828. https://doi.org/10.1126/sciadv.aat7828.

3. Sutton TL, Walker BS, Wong MH. Digesting the importance of cell fusion in the intestine. Cell Mol Gastroenterol Hepatol. 2021;11:299–302. https://doi.org/10.1016/j.jcmgh.2020.07.013.

4. Sutton TL, Walker BS, Wong MH. Circulating hybrid cells join the fray of circulating cellular biomarkers. Cell Mol Gastroenterol Hepatol. 2019;8:595–607. https://doi.org/10.1016/j.jcmgh.2019.07.002.

5. Dietz MS, et al. Relevance of circulating hybrid cells as a noninvasive biomarker for myriad solid tumors. Biorxiv. 2021.2003.2011.434896. doi:https://doi.org/10.1101/2021.03.11.434896 (2021).

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploratory Analyses of Circulating Neoplastic-Immune Hybrid Cells as Prognostic Biomarkers in Advanced Intrahepatic Cholangiocarcinoma;International Journal of Molecular Sciences;2024-08-24

2. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol;BMJ Open;2024-07

3. A systematic review of circulating predictive and prognostic biomarkers to aid the personalised use of radiotherapy in the radical treatment of patients with oesophageal cancer;Radiotherapy and Oncology;2024-06

4. scRNAseq and High-Throughput Spatial Analysis of Tumor and Normal Microenvironment in Solid Tumors Reveal a Possible Origin of Circulating Tumor Hybrid Cells;Cancers;2024-04-08

5. A Case of Esophageal Cancer With Markedly Elevated Soluble Interleukin-2 Receptor: A Potential of Soluble Interleukin-2 Receptor as a Biomarker;Cureus;2024-04-02